The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Primary Ciliary Dyskinesia (PCD) Market During The Forecast Period 2026–2030?
The primary ciliary dyskinesia (pcd) market has experienced robust growth in recent years. It is projected to expand from $0.49 billion in 2025 to $0.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.7%. Historically, the market’s growth was influenced by elements such as limited awareness surrounding pcd, the absence of standardized diagnostic protocols, a dependence on conventional antibiotic therapies, the sparse availability of specialized clinics, and the low adoption rate of airway clearance devices.
The primary ciliary dyskinesia (pcd) market size is anticipated to experience substantial expansion over the next few years. It is projected to reach $0.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period is primarily driven by the advancement of gene therapy and stem cell interventions, increasing investments in diagnostic laboratories, the rising prevalence of rare respiratory disorders, the adoption of personalized medicine approaches, and the integration of digital health and remote monitoring solutions. Furthermore, significant trends expected in this period include the increasing adoption of genetic testing for early diagnosis, a rising use of advanced imaging techniques for monitoring, the expansion of airway clearance therapy devices, a growing demand for personalized antibiotic treatments, and a focus on innovative therapies such as gene and stem cell therapy.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp
What Drivers Are Expected To Influence The Primary Ciliary Dyskinesia (PCD) Market During The Forecast Period?
Increased demand for gene therapy is anticipated to boost the expansion of the primary ciliary dyskinesia market in the future. This therapy involves altering or substituting defective genes within a patient’s cells to treat or avert illnesses. The increasing need for gene therapy stems from advancements in genetic research, which facilitate more precise treatments capable of targeting and rectifying genetic disorders at a molecular level, thereby improving patient results. Scientists are actively developing gene therapy specifically for Primary Ciliary Dyskinesia (PCD) with the aim of correcting genetic mutations responsible for impaired cilia function in the respiratory system. This therapeutic approach introduces healthy genes to re-establish normal ciliary motion, enhance mucus removal, and diminish respiratory infections. As an illustration, in July 2023, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, indicated that in the first quarter of 2023, 247 gene therapy programs were undergoing Phase II clinical trials. This figure subsequently rose by 5%, totaling 260 ongoing Phase II gene therapy trials by the close of the second quarter. Consequently, the escalating demand for gene therapy is fueling the expansion of the primary ciliary dyskinesia market.
What Market Segments Are Evaluated Within The Primary Ciliary Dyskinesia (PCD) Market?
The primary ciliary dyskinesia (pcd) market covered in this report is segmented –
1) By Treatment: Antibiotics, Airway Clearance Therapies, Surgical Interventions, Other Treatments
2) By Method: Genetic Testing, Imaging Techniques, Clinical Evaluation, Lung Function Tests
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Retail Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Antibiotics: Macrolides, Penicillins, Cephalosporins, Fluoroquinolones, Aminoglycosides
2) By Airway Clearance Therapies: Chest Physiotherapy, High-Frequency Chest Wall Oscillation (HFCWO), Positive Expiratory Pressure (PEP) Therapy, Intrapulmonary Percussive Ventilation (IPV), Oscillatory Positive Expiratory Pressure (OPEP)
3) By Surgical Interventions: Sinus Surgery, Tympanostomy Tube Placement, Lung Transplantation
4) By Other Treatments: Mucolytics, Immunomodulatory Therapies, Gene Therapy, Stem Cell Therapy
What Industry Trends Are Redefining The Primary Ciliary Dyskinesia (PCD) Market?
Leading firms within the primary ciliary dyskinesia market are concentrating on creating novel treatments, such as investigational mRNA-based therapeutics, with the goal of better managing symptoms and elevating patients’ quality of life. An investigational mRNA-based therapeutic is an emerging treatment approach where messenger RNA (mRNA) guides cells to synthesize proteins capable of treating or preventing illnesses. This advanced technique addresses conditions at a molecular scale, opening avenues for individualized medicine. As an illustration, in June 2024, ReCode Therapeutics, Inc., a biotechnology company based in the US, introduced RCT1100, which is an investigational inhaled mRNA therapy. It received orphan drug designation approval from the Food and Drug Administration (FDA) specifically for treating primary ciliary dyskinesia. RCT1100 seeks to reinstate ciliary function by directly delivering DNAI1 mRNA to airway cells, addressing a crucial unmet need for the estimated 45,000 affected individuals in the U.S., given the current absence of disease-modifying treatments or cures for PCD.
Who Are The Top Market Participants Influencing The Primary Ciliary Dyskinesia (PCD) Market?
Major companies operating in the primary ciliary dyskinesia (pcd) market are Centogene NV, Revvity Inc, Quest Diagnostics Incorporated, Nationwide Children’s Hospital, Children’s Healthcare of Atlanta, National Jewish Health, Guy’s and St Thomas’ NHS Foundation Trust, University Hospital Southampton, Vanderbilt University Medical Center, Stanford Medicine, Mayo Foundation for Medical Education and Research, UNC School of Medicine, UAB Health System, University Hospital Münster, DNA Labs India Pvt Ltd, Parion Sciences Inc, ReCode Therapeutics Inc, PCD Foundation, PCD Research Consortium, European PCD Network
Read the full primary ciliary dyskinesia (pcd) market report here:
Which Region Is Forecast To Lead The Primary Ciliary Dyskinesia (PCD) Market In Terms Of Market Size?
North America was the largest region in the primary ciliary dyskinesia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (pcd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Primary Ciliary Dyskinesia (PCD) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24386&type=smp
Browse Through More Reports Similar to the Global Primary Ciliary Dyskinesia (PCD) Market 2026, By The Business Research Company
Non Hodgkin Lymphoma Nhl Market Report 2026
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Primary Biliary Cholangitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Non Hodgkin Lymphoma Nhl Market Report 2026
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model